A carregar...
Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers
INTRODUCTION: Immune checkpoint inhibitors (ICIs) are approved in multiple indications for cancer care. Most of the clinical trials have not questioned shorter than until disease progression approaches. In this study, we present results from a cohort of multiple advanced cancers treated with restric...
Na minha lista:
| Publicado no: | J Cancer Res Clin Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Berlin Heidelberg
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7324422/ https://ncbi.nlm.nih.gov/pubmed/32306129 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-020-03217-7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|